E1A, E1B double-restricted adenovirus enhances the cytotoxicity and antitumor activity of gemcitabine to renal cell carcinoma
查看参考文献24篇
|
文摘
|
Background Our previous studies have demonstrated potent oncolysis efficacy of the E1A, E1B double-restricted replication-competent oncolytic adenovirus AxdAdB-3 for treatment of bladder cancer. Here, we reported the feasibility and efficacy of AxdAdB-3 alone, or in combination with gemcitabine for treating renal cell carcinoma. Methods Cytopathic effects of AxdAdB-3 were evaluated in human renal cell carcinoma cell lines TOS-1, TOS-2, TOS-3, TOS-3LN, SMKT-R3, SMKT-R4 and ACHN, and in normal human renal proximal tubule epithelial cells (RPTEC). AxdAdB-3 induced down-regulation of the cell cycle was determined by flow cytometry. Combination therapies of AxdAdB-3 with gemcitabine were evaluated in vitro and in vivo on subcutaneous TOS-3LN tumors in a severe combined immunodeficiency disease (SCID) mouse model. Results AxdAdB-3 was potently cytopathic against the tested most renal cell carcinoma cell lines including TOS-2, TOS-3, TOS-3LN, SMKT-R3 and SMKT-R4, while normal human RPTEC were not destroyed. AxdAdB-3 effectively induced cell cycle S-phase entry. Combined therapy of AxdAdB-3 with gemcitabine demonstrated stronger antitumor effects in vitro and in vivo compared with either AxdAdB-3 or gemcitabine alone. Conclusion AxdAdB-3 alone, or in combination with gemcitabine may be a promising strategy against renal cell carcinoma. |
|
来源
|
Chinese Medical Journal
,2011,124(7):1082-1087 【核心库】
|
|
DOI
|
10.3760/cma.j.issn.0366-6999.2011.07.024
|
|
关键词
|
oncolysis
;
adenovirus
;
gemcitabine
;
renal cell carcinoma
|
|
地址
|
1.
Department of Urology, Zhejiang Cancer Hospital, Zhejiang, Hangzhou, 310022
2.
Department of Urology, Se-en Hospital, Japan, Japan, Tagajyo
3.
Department of Molecular Medicine, Sapporo Medical University, Japan, Japan, Sapporo
4.
Division of Urology, Chair of Surgery Tohoku University Graduate School of Medicine, Japan, Japan, Sendai
|
|
语种
|
英文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
0366-6999 |
|
学科
|
外科学 |
|
基金
|
in part by the Qianjiang Program of Zhejiang Province
|
|
文献收藏号
|
CSCD:4428515
|
参考文献 共
24
共2页
|
|
1.
Jemal A. Cancer statistics, 2009.
CA Cancer J Clin,2009,59:225-249
|
CSCD被引
554
次
|
|
|
|
|
2.
Culine S. Subcutaneous interleukin-2 and interferon-alpha in metastatic renal cell carcinoma: results of a French regional experience in Languedoc.
Am J Clin Oncol,2006,29:148-152
|
CSCD被引
3
次
|
|
|
|
|
3.
Jonasch E. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities.
Oncologist,2001,6:34-55
|
CSCD被引
23
次
|
|
|
|
|
4.
Fisher R I. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma.
Cancer J Sci Am,2000,6:55-57
|
CSCD被引
2
次
|
|
|
|
|
5.
Motzer R J. Sunitinib in patients with metastatic renal cell carcinoma.
JAMA,2006,295:2516-2524
|
CSCD被引
34
次
|
|
|
|
|
6.
Motzer R J. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
N Engl J Med,2007,356:115-124
|
CSCD被引
117
次
|
|
|
|
|
7.
Hiles J J. Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma.
Am J Health Syst Pharm,2008,65:123-131
|
CSCD被引
5
次
|
|
|
|
|
8.
Wang H. Oncolytic viral therapy by bladder instillation using an E1A, E1B double-restricted adenovirus in an orthotopic bladder cancer model.
Urology,2006,68:674-681
|
CSCD被引
3
次
|
|
|
|
|
9.
Rini B I. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma.
Cancer,2005,103:553-558
|
CSCD被引
1
次
|
|
|
|
|
10.
Plunkett W. Gemcitabine: preclinical pharmacology and mechanisms of action.
Semin Oncol,1996,23(5 Suppl 10):3-15
|
CSCD被引
7
次
|
|
|
|
|
11.
Tonkinson J L. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma.
Cancer Res,1999,59:3671-3676
|
CSCD被引
5
次
|
|
|
|
|
12.
Kelley J R. CaSm/gemcitabine chemo-gene therapy leads to prolonged survival in a murine model of pancreatic cancer.
Surgery,2001,130:280-288
|
CSCD被引
3
次
|
|
|
|
|
13.
Fueyo J. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo.
Oncogene,2000,19:2-12
|
CSCD被引
18
次
|
|
|
|
|
14.
Hecht J R. A phase I/II trial of intratumoral endoscopic ultrasound injection of ONYX-015 with intravenous gemcitabine in unresectable pancreatic carcinoma.
Clin Cancer Res,2003,9:555-561
|
CSCD被引
20
次
|
|
|
|
|
15.
Satoh M. Four new human renal cell carcinoma cell lines expressing globo-series gangliosides.
Tohoku J Exp Med,1999,189:95-105
|
CSCD被引
1
次
|
|
|
|
|
16.
Miyao N. Establishment of three human renal cell carcinoma cell lines (SMKT-R-1, SMKT-R-2, and SMKT-R-3) and their characters.
Urol Res,1989,17:317-324
|
CSCD被引
1
次
|
|
|
|
|
17.
Otani N. Study on in vitro invasive potential of renal cell carcinoma cell lines and effect of growth factors (EGF and TGF-β1) on their in invasions.
Nippon Hinyokika Gakkai Zasshi,1991,82:613-619
|
CSCD被引
2
次
|
|
|
|
|
18.
Braakhuis B J. Schedule-dependent antitumor effect of gemcitabine in in vivo model system.
Semin Oncol,1995,22(4 Suppl 11):42-46
|
CSCD被引
1
次
|
|
|
|
|
19.
Fukuda K. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer.
Cancer Res,2003,63:4434-4440
|
CSCD被引
6
次
|
|
|
|
|
20.
Khuri F R. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
Nat Med,2000,6:879-885
|
CSCD被引
44
次
|
|
|
|
|
了解气象卫星更多信息，请访问